Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.49 |
| ▸ | P2RY12 | Q9H244 | 6/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13964744 | 1.00 | PRMT6 (0.49) | PRMT6BMPR1BP2RY12ADORA1ADORA3 | |
| SCHEMBL25496184 | 1.00 | PRMT6 (0.49) | PRMT6BMPR1BP2RY12ADORA1ADORA3 | |
| SCHEMBL18464550 | 0.93 | ADORA1 (0.53) | P2RY12ADORA1ADORA3 | |
| SCHEMBL26534345 | 0.93 | ADORA1 (0.53) | P2RY12ADORA1ADORA3 | |
| SCHEMBL20149806 | 0.93 | ADORA1 (0.53) | P2RY12ADORA1ADORA3 | |
| SCHEMBL25496182 | 0.93 | ADORA1 (0.53) | P2RY12ADORA1ADORA3 | |
| SCHEMBL13396719 | 0.93 | ADORA1 (0.53) | P2RY12ADORA1ADORA3 | |
| SCHEMBL26297899 | 0.92 | PRMT6 (0.52) | PRMT6BMPR1BP2RY12ADORA1ADORA3 | |
| SCHEMBL25496185 | 0.91 | BMPR1B (0.53) | BMPR1BP2RY12ADORA1ADORA3 | |
| SCHEMBL26297894 | 0.91 | BMPR1B (0.53) | BMPR1BP2RY12ADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | PRMT6 1699/4885BMPR1B 2854/4885P2RY12 3542/4885 |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | PRMT6 1699/4885BMPR1B 2854/4885P2RY12 3542/4885 |
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | NSUN2, ADAR, POLM | PRMT6 597/4885BMPR1B 2485/4885P2RY12 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.